Institute for Health Research and Policy, University of Illinois at Chicago, M/C 275, 1747 West Roosevelt Road, Chicago, IL 60608, USA.
Breast Cancer Res Treat. 2012 Oct;135(3):663-80. doi: 10.1007/s10549-012-2200-8. Epub 2012 Aug 19.
Body composition changes cannot be precisely captured using body weight or body mass index measures. Therefore, the primary purpose of this review was to characterize the patterns of body composition change in females treated for breast cancer including only studies that utilize imaging technologies to quantify adipose tissue and lean body mass (LBM). We reviewed PubMed for studies published between 1971 and 2012 involving females diagnosed with breast cancer where computed axial tomography , dual-energy X-ray absorptiometry, or magnetic resonance imaging were employed for body composition assessment. Of the initial 440 studies, 106 papers were evaluated and 36 papers met all eligibility criteria (15 observational and 21 intervention trials). Results of these studies revealed that body weight did not consistently increase. Importantly, studies also showed that body weight did not accurately depict changes in lean or adipose tissues. Further findings included that sarcopenic obesity as a consequence of breast cancer treatment was not definitive, as menopausal status may be a substantial moderator of body composition. Overall, the behavioral interventions did not exhibit consistent or profound effects on body composition outcomes; approximately half showed favorable influence on adiposity while the effects on LBM were not apparent. The use of tamoxifen had a clear negative impact on body composition. The majority of studies were conducted in predominantly white survivors, highlighting the need for trials in minority populations. Collectively, these studies were limited by age, race, and/or menopause status matched control groups, overall size, and statistical power. Very few studies simultaneously collected diet and exercise data-two potential factors that impact body composition. Future breast cancer trials should prioritize precise body composition methodologies to elucidate how these changes impact recurrence, prognosis, and mortality, and to provide clinicians with appropriate advice regarding lifestyle recommendations in this growing sector of the population.
身体成分的变化不能通过体重或体重指数来准确捕捉。因此,本综述的主要目的是描述女性乳腺癌治疗中身体成分变化的模式,包括仅使用影像学技术来定量脂肪组织和瘦体重(LBM)的研究。我们在 PubMed 上检索了 1971 年至 2012 年期间发表的涉及女性乳腺癌诊断的研究,其中使用计算机轴向断层扫描、双能 X 射线吸收测定法或磁共振成像来评估身体成分。在最初的 440 项研究中,有 106 篇论文进行了评估,其中 36 篇论文符合所有入选标准(15 项观察性研究和 21 项干预性试验)。这些研究的结果表明,体重并没有持续增加。重要的是,研究还表明,体重并不能准确地描述瘦组织或脂肪组织的变化。进一步的发现包括,由于乳腺癌治疗而导致的肌肉减少性肥胖并不是确定的,因为绝经状态可能是身体成分的一个重要调节剂。总的来说,行为干预对身体成分结果没有表现出一致或显著的影响;大约一半的研究对肥胖有有利的影响,而对 LBM 的影响则不明显。使用他莫昔芬对身体成分有明显的负面影响。大多数研究都是在以白种人幸存者为主的人群中进行的,这突出了在少数人群中进行试验的必要性。总的来说,这些研究受到年龄、种族和/或绝经状态匹配对照组、总体规模和统计能力的限制。很少有研究同时收集饮食和运动数据——这两个可能影响身体成分的因素。未来的乳腺癌试验应该优先采用精确的身体成分方法学,以阐明这些变化如何影响复发、预后和死亡率,并为临床医生提供有关这一人群中生活方式建议的适当建议。